Global News Aggregator
Biopharma companies are having more clinical success treating Alzheimer’s disease and obesity and are taking new approaches in oncology, and that’s creating more mega-blockbuster drugs, according to Bank of America.…
Eli Lilly’s drug tirzepatide has been granted “fast track” status by the Food and Drug Administration, which means it could win approval to be prescribed as an obesity treatment as…
Check out the companies making headlines before the bell: Conagra (CAG) – The food producer’s stock added 2% in the premarket after it reported better-than-expected quarterly profit and sales. Conagra…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. Stocks teeter Selling high, considering…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. Market gets an oversold bounce…
We don’t own Eli Lilly exclusively for its potential Alzheimer’s treatment. However, we still find Biogen’s topline data to be very encouraging for Lilly. Source link: https://www.cnbc.com/2022/09/28/heres-why-biogens-promising-alzheimers-drug-data-is-also-good-news-for-eli-lilly-.html
Check out the companies making headlines before the bell: Accenture (ACN) – The consulting firm reported a better-than-expected quarterly profit and revenue, but gave a weaker-than-expected revenue forecast for the…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. We have no choice but…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. The market needs a break…
CNBC’s Jim Cramer gave investors advice on how to build a strong portfolio during the Federal Reserve’s struggle to reduce inflation. Source link: https://www.cnbc.com/2022/09/15/heres-how-were-positioned-in-four-sectors-and-some-of-the-stocks-we-like-in-each.html